

Imidazolidinyl Urea

Christina Burnett*, Wilma F. Bergfeld**, Donald V. Belsito**, Curtis D. Klaassen**, Daniel C. Liebler***, James G. Marks***, Ronald C. Shank***, Thomas J. Slaga**, Paul W. Snyder**, Monice Fiume[†], and Bart Heldreth[‡]

International Journal of Toxicology 2023, Vol. 42(Supplement 3) 53S–55S © The Author(s) 2023 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/10915818231204614 journals.sagepub.com/home/ijt



Abstract

The Expert Panel for Cosmetic Ingredient Safety reviewed updated information that has become available since their original assessment from 1980, along with updated information regarding product types, and frequency and concentrations of use, and reaffirmed their original conclusion that Imidazolidinyl Urea is safe as a cosmetic ingredient in the practices of use and concentration as described in this report.

Keywords

Safety, Cosmetics, Imidazolidinyl Urea

The Expert Panel for Cosmetic Ingredient Safety first published the Final Report on the Safety Assessment of Imidazolidinyl Urea in 1980. The Expert Panel concluded that this ingredient was safe when incorporated in cosmetic products in amounts similar to those presently marketed, as described in that report. In 2001, after considering new studies and updated use data on this ingredient, the Expert Panel determined to not re-open the safety assessment.² Data identified in the published literature³⁻³¹ that have become available since the 2001 re-review was issued support the conclusion reached by the Expert Panel in the original review. The Expert Panel also reviewed updated information regarding product types and ingredient use frequencies as reported in the US Food and Drug Administration (FDA) Voluntary Cosmetic Registration Program (VCRP) database, 32 and the maximum use concentrations provided by the Personal Care Products Council (Council).³³ The Expert Panel determined to not re-open this safety assessment and reaffirmed the original conclusion that Imidazolidinyl Urea is safe as a cosmetic ingredient in the present practices of use and concentration, as given in Table 1.

The reported frequency of use for this ingredient has decreased significantly since the initial re-review was considered. According to VCRP data, Imidazolidinyl Urea was reported to be used in 2025 formulations in 2001.² In 2019, VCRP data indicate that Imidazolidinyl Urea is used in 1558 formulations.³² The current maximum concentration of use (0.6%) in leave-on products,³³ according to the Council, is approximately the same as that reported in 2001 (0.7%).²

The Expert Panel noted that Imidazolidinyl Urea is a formaldehyde-releasing preservative, and use of these types of

ingredients as a whole has decreased. The Expert Panel determined that there were no new relevant data that necessitated a new re-review of this ingredient.

Author Contributions

The articles in this supplement were sponsored by the Cosmetic Ingredient Review.

Author's Note

Unpublished sources cited in this report are available from the Director, Cosmetic Ingredient Review, 1620 L Street, NW, Suite 1200, Washington, DC 20036, USA.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Corresponding Author:

Bart Heldreth, Executive Director, Cosmetic Ingredient Review, 1620 L Street, NW, Suite 1200, Washington, DC 20036, USA. Email: cirinfo@cir-safety.org

^{*}Cosmetic Ingredient Review Senior Scientific Analyst/Writer, Washington, DC, USA

^{**}Expert Panel for Cosmetic Ingredient Safety Member

^{***}Expert Panel for Cosmetic Ingredient Safety Former Member

[†]Cosmetic Ingredient Review Senior Director

[‡]Cosmetic Ingredient Review Executive Director

	# of Uses		Max Conc of Use (%)	
	2019 ³²	2001 ²	2018 ³³	200 I ²
Totals*	1558	2025	.0000004-0.6	.01-1
Duration of use				
Leave-on	1217	1576	.0002-0.6	.01-0.7
Rinse-off	335	363	.0000004-0.5	.1-1
Diluted for (bath) use	6	86	NR	.2-0.5
Exposure type				
Eye area	336	433	.2-0.5	.01-0.6
Incidental ingestion	2	П	0.2	0.4
Incidental inhalation-spray	2; 367 ^a ; 269 ^b	32; 369 ^a ; 202 ^b	.2-0.6 ^a	.45; .2-0.6 ^{a,b}
Incidental inhalation-powder	82; 269 ^b ; 2 ^c	88; 202 ^b ; 2 ^c	.2; .3-0.5°	.24; .2-0.6 ^b .3-0.6 ^c
Dermal contact	1277	1814	.000024-0.5	.01-1
Deodorant (underarm)	3 ^a	4 ^a	0.3 ^a	0.4 ^a
Hair – non-coloring	152	125	.0000004-0.6	.2-0.5
Hair-coloring	91	6	.0006-0.3	.2-0.4
Nail	6	10	.000235	.2-0.5
Mucous membrane	42	138	.00008-0.3	.2-0.5
Baby products	4	4	NR	.3-0.6

Table 1. Current and Historical Frequency and Concentration of Use of Imidazolidinyl Urea According to Duration and Exposure.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The articles in this supplement were sponsored by the Cosmetic Ingredient Review. The Cosmetic Ingredient Review is financially supported by the Personal Care Products Council.

References

- Elder RL, ed. Final report of the safety assessment for imidazolidinyl urea, J Environ Pathol Toxicol 1980; 4: 133-146.
- Andersen FA, ed. Imidazolidinyl urea, Int J Toxicol 2003; 22: 15-17.
- Nikitakis J, Kowcz A. Web-Based International Cosmetic Ingredient Dictionary and Handbook. Washington, DC: Personal Care Products Council; 2019. Last Updated http://webdictionary. personalcarecouncil.org/jsp/Home.jsp. (Accessed 29 March, 2019).
- Lv C, Hou J, Xie W, Cheng H. Investigation on formaldehyde release from preservatives in cosmetics. *Int J Cosmet Sci.* 2015; 37:474-478.
- Lehmann S, Hoeck U, Breinholdt J, Olsen C, Kreilgaard B. Characterization and chemistry of imidazolidinyl urea and diazolidinyl urea. *Contact Dermatitis*. 2006;54:50-58.
- Doi T, Takeda A, Asada A, Kajimura K. Characterization of the decomposition of compounds derived from imidazolidinyl urea in cosmetics and patch test materials. *Contact Dermatitis*. 2012; 67:284-292.

- European Union. 2009. Regulation (EC) No. 1223/2009 of the European Parliament and of the Council of 30 November 2009 On Cosmetic Products
- National Industrial Chemicals Notification and Assessment Scheme (NICNAS). Final Report on Hazard Classification of Common Skin Sensitisers. NICNAS. www.nicnas.gov.au. 2005.
- Babar N, Kim M, Cao K, et al. Cosmetic preservatives as therapeutic corneal and scleral tissue cross-linking agents. *Invest Ophthalmol Vis Sci.* 2015;56(2):1274-1282.
- 10. European Chemicals Agency (ECHA). *N,N"-methylenebis[N'-[3-(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]urea]*. https://echa.europa.eu/registration-dossier/-/registered-dossier/10553. 2019. (Accessed 29 March, 2019).
- Hossy B, da Costa Leitao A, dos Santos E, et al. Phototoxic assessment of a sunscreen formulation and its excipients: an in vivo and in vitro study. *J Photochem Photobiol*, B. 2017;173: 545-550.
- Placzek M, Krosta I, Gaube S, Eberlein-Konig B, Przybilla B. Evaluation of phototoxic properties of antimicrobials used in topical preparations by a photohaemolysis test. *Acta Derm Venereol.* 2005;85:13-16.
- Agner T, Andersen K, Bjorkner B, et al. Standardization of the TRUE Test imidazolidinyl urea and diazolidinyl urea patches. Contact Dermatitis. 2001;45:21-25.
- Rietschel R, Warshaw E, Sasseville D, et al. Sensitivity of petrolatum and aqueous vehicles for detecting allergy to imidazolidinylurea, diazolidinylurea, and DMDM hydantoin: a

^{*}Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.

^alt is possible these products are sprays, but it is not specified whether the reported uses are sprays.

^bNot specified whether a spray or a powder, but it is possible the use can be as a spray or a powder; therefore, the information is captured in both categories. ^cIt is possible these products are powders, but it is not specified whether the reported uses are powders.

NR, not reported.

Burnett et al. 55S

- retrospective analysis from the North American Contact Dermatitis Group. *Dermatitis*. 2007;18(3):155-162.
- Ando M, Ansotefui I, Munoz D, deCorres L. Allergic contact dermatitis from imidazolidinyl urea in an ultrasonic gel. *Contact Dermatitis*. 2000;42:109-110.
- Garcia-Gavin J, Gonzalez-Vilas D, Fernandez-Redondo V, Toribo J. Allergic contact dermatitis in a girl due to several cosmetics containing diazolidinyl-urea or imidazolidinyl-urea. Contact Dermatitis. 2010;63:49-50.
- Landeck L, Gonzalez E, Baden L, Neumann K, Schalock P. Positive concomitant test reactions to allergens in the standard patch test series. *Int J Dermatol*. 2010;49:517-519.
- 18. Chow E, Avolio A, Lee A, Nixon R. Frequency of positive patch test reactions to preservatives: the Australian experience. *Australas J Dermatol.* 2013;54:31-35.
- Shaughnessy C, Malajian D, Belsito D. Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis: Reactivity to topical preservatives. *J Am Acad Dermatol*. 2013;70(1):102-107.
- Warshaw E, Raju S, Fowler J, et al. Positive patch test reactions in older individuals: Retrospective analysis from the North American Contact Dermatitis Group, 1994-2008. *J Am Acad Dermatol*. 2012;66(2):229-240.
- Thyssen J, Engkilde K, Lundov M, Carlsen B, Menne T, Johansen J. Temporal trends of preservative allergy in Denmark (1985-2008). *Contact Dermatitis*. 2010;62:102-108.
- 22. Schnuch A, Lessmann H, Geier J, Uter W. Contact allergy to preservatives. Analysis of IVDK data 1996-2009. *Br J Dermatol*. 2011;164:1316-1325.
- Britton J, Wilkinson S, English J, et al. The British standard series of contact dermatitis allergens: Validation in clinical practice and value for clinical governance. *Br J Dermatol*. 2003;148(2):259-264.
- Boyvat A, Akyol A, Gurgey E. Contact sensitivity to preservatives in Turkey. *Contact Dermatitis*. 2005;52:329-332.

- Dastychova E, Necas M, Vasku V. Contact hypersensitivity to selected excipients of dermatological topical preparations and cosmetics in patients with chronic eczema. *Acta Dermatoven* APA. 2008;17(2):61-68.
- Cheng S, Cao M, Zhang Y, et al. Time trends of contact allergy to a modified European baseline series in Beijing between 2001 and 2006. *Contact Dermatitis*. 2011;65(1):22-27.
- Toholka R, Wang Y-S, Tate B, et al. The first Australian Baseline Series: Recommendations for patch testing in suspected contact dermatitis. *Australas J Dermatol*. 2015;56:107-115.
- 28. Jong C, Statham B, Green C, et al. Contact sensitivity to preservatives in the UK, 2004-2005: results of multicentre study. *Contact Dermatitis*. 2007;57:165-168.
- Cheng S, Leow Y, Goh C, Goon A. Contact sensitivity to preservatives in Singapore: frequency of sensitization to 11 Common preservatives 2006-2011. *Dermatitis*. 2014;25(2): 77-82.
- 30. Warshaw E, Maibach H, Taylor J, et al. North American contact dermatitis Group patch test results: 2011-2012. *Dermatitis*. 2015;26(1):49-59.
- Wang W, Li L, Wang J. Cosmetic dermatitis in Chinese eczema patients patch tested with a modified European standard series of allergens. *Contact Dermatitis*. 2005;53(6):314-319.
- 32. Us Food and Drug Administration (Fda) Center for Food Safety & Applied Nutrition (Cfsan). Voluntary cosmetic Registration Program (VCRP) frequency of Use of cosmetic ingredients. College Park, MD: (Obtained under the Freedom of information Act from CFSAN; requested as "frequency of Use data". 2019. January 3 2019; received February 13, 2019.)
- 33. Personal Care Products Council. *Concentration of Use by FDA Product Category: Imidazolidinyl Urea*; 2018. (Unpublished data submitted by Personal Care Products Council).